A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors

2024-513692-41-00 Protocol D9723C00002 Human pharmacology (Phase I) - Other Ended

Start 11 Jun 2025 · End 1 May 2026 · Status Ended · 2 EU/EEA countries · 3 sites · Protocol D9723C00002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 45
Countries 2
Sites 3

advanced solid malignancies

Key facts

Sponsor
AstraZeneca AB
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
11 Jun 2025 → 1 May 2026
Decision date (initial)
2025-05-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

advanced solid malignancies

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
-
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Public contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 9 1
Romania Ended 24 2
Rest of world
Moldova, Republic of
12

Investigational sites

Bulgaria

1 site · Ended
Multispecialty hospital for active treatment Sveta Sofia EOOD
0901: Department of Medical Oncology, Bulevard Bilgariya 104, 1404, Sofiya

Romania

2 sites · Ended
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
6102: Radiotherapy, Strada Republicii 34-36, 400015, Cluj-Napoca
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
6101: Oncology, Soseaua Fundeni 252, 022328, Bucharest

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-06-13 2026-02-26 2025-08-22 2025-12-10
Romania 2025-06-11 2026-04-30 2025-06-13 2026-01-15

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-05 Bulgaria Acceptable
2025-05-21
2025-05-22
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-30 Bulgaria Acceptable
2025-09-16
2025-09-22
3 SUBSTANTIAL MODIFICATION SM-2 2026-03-03 Bulgaria Acceptable
2026-05-07
2026-05-11